AUS
NZ
UK
CA
USA
IND
Highlights
Preclinical results indicate tumour growth blockage in triple-negative breast cancer models
Activity observed as a monotherapy, broadening therapeutic scope
Plans to advance towards phase two clinical trials after phase one data release
Percheron Therapeutics Ltd (ASX:PER) operates in the biotechnology sector and is a constituent of the ASX 300. The company recently shared developments on its investigational cancer treatment HMBD-002, reporting encouraging results from preclinical studies targeting aggressive forms of breast cancer. These updates come alongside the company’s ongoing clinical research initiatives, with further data anticipated from its human trials later in the year.
Preclinical performance in triple-negative breast cancer
The latest preclinical study revealed that HMBD-002 was able to substantially hinder tumour growth in a triple-negative breast cancer model using laboratory mice. This follows earlier positive results in head and neck cancer research, where the therapy was used in combination with radiotherapy. The recent findings highlight the drug’s ability to act effectively as a standalone treatment.
Activity beyond immune modulation
HMBD-002 has been designed to engage the immune system in targeting tumour cells. The new breast cancer data points to the possibility of additional mechanisms of action that may differentiate it from other immune-based treatments, such as Keytruda. The observation of anti-tumour activity as a monotherapy opens pathways for further exploration in multiple cancer types.
Pathway towards phase two trials
The company has completed a phase one human clinical trial of HMBD-002, with final data expected before the end of the year. This information will guide the development strategy for upcoming phase two trials. The next stage will focus on determining the most effective applications for the therapy across various oncology indications.
Building on prior oncology research
Earlier studies in head and neck cancer demonstrated HMBD-002’s effectiveness when paired with radiotherapy. The latest findings in breast cancer suggest versatility, as the drug has shown promising activity without the need for combination therapies. This strengthens the case for further clinical evaluation in different cancer types.
Strategic research direction
Percheron Therapeutics Ltd (OTC:PERCF) continues to expand its oncology research portfolio, with HMBD-002 as a lead candidate. The company is refining its clinical roadmap to optimise therapeutic benefits for cancer patients. The outcomes from the upcoming phase one data review will be instrumental in defining the scope and design of phase two trials.
Frequently Asked Questions
- What does Percheron Therapeutics focus on?
The company specialises in developing cancer immunotherapies. - What is HMBD-002?
It is an experimental therapy aimed at targeting tumour growth through immune modulation and other mechanisms. - When will phase two trials begin?
Plans for phase two will follow the completion and review
